Mayor Wee urges vigilance as Sarawak logs three more rabies cases
KUCHING (July 13): Sarawak recorded three rabies cases from July 7 to 11, two of which involved stray dogs, said Kuching South Mayor Dato Wee Hong Seng.
According to him, the two positive cases involving stray dogs occurred in Moyan Square, Batu Kawah, and Bintulu.
'The other case involved a pet dog from Lorong 3, Taman Sri Moyan, Batu Kawah,' he said during his Facebook live 'Shall WEE Talk' yesterday.
Wee said all dog owners are required to send their pets for anti-rabies vaccination regularly, as stipulated under Section 40 of the Veterinary Public Health Ordinance 1999.
Failing this, he said they will face a fine not exceeding RM2,500.
He added that dog owners who fail to show proof of vaccination may also face legal action.
Pointing out that rabies remains a public health threat to Sarawakians, the Mayor urged everyone to remain vigilant and do what they must to curb its spread.
Wee also called upon pet owners to bring their dogs for the jab at a mass anti-rabies vaccination campaign to be held at the MBKS Dewan Masyarakat on Sept 20, in conjunction with the World Rabies Day.
He said another similar drive is scheduled to take place at the Sarawak Basketball Association's premises in Taman Seng Goon on Oct 4.
'MBKS has been organising free anti-rabies vaccination programmes, and the last of its kind was held at the Mayor Song Swee Guan Park in Tabuan Jaya.'
Wee hoped that dog owners will seize these opportunities to make sure that their pets are vaccinated against rabies.
He said this is a move to protect not just their own pets but also their family and the community at large.
He also reminded all that rabies is fatal, and that prevention is better than cure. lead new cases rabies vaccination drive wee hong seng
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 days ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
Borneo Post
3 days ago
- Borneo Post
Milestone for Sarawak's livestock sector as 800 live pigs shipped to Selangor
Dr Rundi (sixth left) leads the ribbon cutting to officially launch of the shipment. – Photo by Chimon Upon KUCHING (July 25): Sarawak's livestock export industry achieved another milestone here today with the official shipment of 800 live pigs to Selangor. Food Industry, Commodity and Regional Development Minister Dato Sri Dr Stephen Rundi Utom described the occasion as a significant step in the state's journey towards becoming a net food exporter by 2030. 'Today we are witnessing 800 heads of pig all the way to Selangor. This event is indeed very significant. In fact, it is a historic moment that we have to share not only with Sarawakians, but also with Malaysians and the world – that we are now able to export live pigs. 'And in the future, perhaps poultry and more. This has been a dream for us. Becoming a net food exporter by 2030 is a gigantic task, but nonetheless, we are making it happen. 'Once people see that it can be done, they get motivated. And once they believe it's possible, the rest is just history,' he told reporters at the official loading ceremony at Pending Port. The shipment is expected to arrive in Klang within 60 hours or approximately two and a half days. Dr Rundi said this first shipment to Peninsular Malaysia would not be the last. 'In the future, there will be bigger shipments and consignment containers that we send to Selangor. They can have the abattoir in Selangor and the meat can be distributed all throughout West Malaysia. And also the plan is to send directly to Penang and Johor,' he said. The pigs were supplied by Green Breeder Sdn Bhd, a Sarawak-based company led by Dr Ng Siew Thiam and his family, who currently export approximately 2,000 pigs weekly to Singapore. Dr Rundi commended the company's efforts and biosecurity standards, noting their success in maintaining exports even during the African Swine Fever (ASF) outbreak that impacted many other regions. 'Sarawak has been fortunate to remain an exporter of live pigs to Singapore, and now, other Asean countries may also be looking at us in the same light. 'Sarawak is free from foot and mouth disease (FMD) and that gives us a real advantage and leverage in attracting investors and encouraging more livestock farming activities here in the state,' he explained. Dr Rundi pointed out Sarawak first began exporting live pigs to Singapore in 2017, starting with a farm in Simunjan. He said the initial goal was to involve smallholder farmers, but biosecurity and technological requirements proved challenging. 'Not many could survive under such tight protocols, so we had to move from subsistence farming to high tech. Dr Ng told me they are going all the way with high-tech systems and biosecurity. That's why they can survive,' he said. To support the livestock sector's growth, Dr Rundi said the state will establish a new School of Veterinary Medicine in Semenggok through a collaboration with Universiti Putra Malaysia (UPM) Sarawak, formerly known as UPM Bintulu Campus. 'At the moment, we are lacking veterinarians. We need many more to manage and support the livestock industry. 'When we visited Brazil, they had 4,000 vets looking after their cattle. Here, we have only 15 government vets handling everything, while the rest are private. So, it has to be comprehensive – we must plan everything properly so that we can realise the dream we have. 'With this initiative, we can plan more effectively for the future of the livestock and agricultural sectors in Sarawak. I see great potential for Sarawak to become an agricultural hub,' he added. On the issue of pork prices, Dr Rundi said the government is monitoring the situation, but market rates are ultimately driven by supply and demand. 'When you talk about business, it's supply and demand. What we need now is to increase the supply to help reduce the price. 'At the moment, the supply is limited, so prices go up. That's why everyone is craving for it and they have to pay for it. But if we can increase production and volume, we will have better control over supply and pricing,' he said. He explained that the government is taking steps to prevent prices from soaring too high. 'At the moment, the price is around RM32 per kg. In Sabah, it's RM45, and in West Malaysia, even more — over RM40 to RM45 in the Klang Valley. We are the cheapest now. We cannot complain — but still we complain,' he added. Among those present at the event were Deputy Minister for Modernisation of Agriculture and Regional Development Datuk Martin Ben, Department of Veterinary Services Sarawak director Datu Dr Adrian Susil, Kuching Port Authority general manager Robert Lau Hong Thiam, Sarawak Agriculture Department director Dominic Chunggat, and Green Breeder Sdn Bhd director Dr Ng Yong Han. Dr Stephen Rundi Utom livestock
The Star
4 days ago
- The Star
Meta unveils wristband for controlling computers with hand gestures
SAN FRANCISCO: The prototype looks like a giant rectangular wristwatch. But it doesn't tell the time: It lets you control a computer from across the room simply by moving your hand. With a gentle turn of the wrist, you can push a cursor across your laptop screen. If you tap your thumb against your forefinger, you can open an app on your desktop computer. And when you write your name in the air, as if you were holding a pencil, the letters will appear on your smartphone. Designed by researchers at Meta, the tech giant that owns Facebook, Instagram and WhatsApp, this experimental technology reads the electrical signals that pulse through your muscles when you move your fingers. These signals, generated by commands sent from your brain, can reveal what you are about to do even before you do it, as the company detailed in a research paper published Wednesday in the journal Nature . With a little practice, you can even move your laptop cursor simply by producing the right thought. 'You don't have to actually move,' Thomas Reardon, the Meta vice president of research who leads the project, said in an interview. 'You just have to intend the move.' Meta's wristband is part of a sweeping effort to develop technologies that let wearers control their personal devices without touching them. The aim is to provide simpler, quicker and less awkward ways of interacting with everything from laptops to smartphones – and maybe even to develop new digital devices that replace what we all use today. Most of these technologies are years away from widespread use. They typically involve tiny devices surgically implanted in the body, which is a complicated and risky endeavor. These implants are tested solely with disabled people who cannot move their arms and hands, and need new ways of using computers or smartphones. Neuralink, a Silicon Valley startup founded by Elon Musk, aims to implant chips under the skull, beside the brain. Synchron, run by an Australian neurologist, hopes to implant devices inside blood vessels in the neck. These efforts, like those of many other startups, aim to read brain activity directly – an enormously complex process that must be tailored to the individual. Meta is taking a simpler approach. Its technology does not require surgery. Anyone can strap on the device and start using it. Using artificial intelligence techniques, Reardon and his team have identified common electrical signals that appear when a person moves a finger, wrist or thumb. 'This idea – this kind of technology – is not new, it is decades old,' said Dario Farina, a professor of bioengineering at Imperial College, London, who has tested the technology but was not involved in the research. 'The breakthrough here is that Meta has used artificial intelligence to analyse very large amounts of data, from thousands of individuals, and make this technology robust. It now performs at a level it has never reached before.' Meta's wristband uses a technique called electromyography, or EMG, to gather electrical signals from muscles in the forearm. These signals are produced by neurons in the spinal cord – called alpha motor neurons – that connect to individual muscle fibers. Because these neurons connect directly to the muscle fibers, the electrical signals are particularly strong – so strong that they can be read from outside the skin. The signal also moves much faster than the muscles. If a device like Meta's wristband can read the signals, it can type much faster than your fingers. 'We can see the electrical signal before you finger even moves,' Reardon said. EMG has long provided a way for amputees to control prosthetic hands. But technologies that use the technique as a computer interface are only beginning to mature. In 2012, three Canadian entrepreneurs founded a company called Thalmic Labs, which built an armband called Myo that sent simple computer commands using hand gestures. With the swipe of a hand, for instance, you could switch to a new slide in a PowerPoint presentation. But the company discontinued the product several years later. Reardon started similar research after founding a company called Ctrl Labs with two other neuroscientists he had met in a Ph.D. program at Columbia University. In 2019, the startup was acquired by Meta, where it now operates within a research operation called Reality Labs. Although Reardon and his colleagues have been privately demonstrating their technology for years, they are only now beginning to publicly share their work because it is now mature enough for the marketplace. The key development is the use of AI techniques to analyse the EMG signals. After collecting these signals from 10,000 people who agreed to test the prototype, Reardon used a machine learning system called a neural network – the same breed of AI that drives ChatGPT – to identify common patterns in this data. Now, it can look for these same patterns even when a different person is using the device. 'Out of the box, it can work with a new user it has never seen data for,' said Patrick Kaifosh, director of research science at Reality Labs and one of the neuroscientists that founded Ctrl Labs. According to Reardon, who is also known as the founding father of the Internet Explorer web browser at Microsoft, Meta plans to fold the technology into products over the next few years. Last fall, the company demonstrated how its wristband could be used to control an experimental version of its smart glasses, which can take photos, record videos, play music and verbally describe the world around you. Like technologies from Neuralink and Synchron, Meta's wristband could also provide new options for disabled people. Researchers at Carnegie Mellon are testing the wristband with people who have spinal cord injuries, allowing them to use smartphones and computers even though they do not have full use of their arms or hands. Most people with these types of injuries retain the ability to activate at least some of their muscle fibers. This allows the device to read what their brain is trying to do, even though their bodies can't actually make it happen. 'We can see their intention to type,' said Douglas Weber, a professor of mechanical engineering and neuroscience at Carnegie Mellon. In a similar way, Meta's wristband lets you control a computer with the appropriate thought. Merely thinking about a movement is not enough. But if you intend to make a movement, the wristband can pick up on what you aim to do – even if you do not physically move. 'It feels like the device is reading your mind, but it is not,' Reardon said. 'It is just translating your intention. It sees what you are about to do.' When you move your arm or hand or finger, the number of muscle fibers you activate varies depending on how big or how small the movement is. If you practice using the wristband long enough, you can learn to activate a tiny number of fibers without actually moving your fingers. 'We can listen to a single neuron. We are working at the atomic level of the nervous system.' – ©2025 The New York Times Company This article originally appeared in The New York Times.
